Roche Group's Genentech Announces FDA Approves Ocrevus Zunovo As The First And Only Twice-A-Year 10-Minute Subcutaneous Injection For People With Relapsing And Progressive Multiple Sclerosis
Roche Group's Genentech Announces FDA Approves Ocrevus Zunovo As The First And Only Twice-A-Year 10-Minute Subcutaneous Injection For People With Relapsing And Progressive Multiple Sclerosis
– Ocrevus Zunovo has the potential to expand treatment options to centers without IV infrastructure or with IV constraints, like at a doctor's office –
– Ocrevus Zunovo有潛力擴大治療選項，以滿足沒有靜脈製造行業設施或存在靜脈限制的中心，例如醫生辦公室 –
– This approval is backed by a decade of proven safety and efficacy data of Ocrevus IV, with over 350,000 people treated globally –
– 這一批准是基於超過350,000人全球接受治療的Ocrevus靜脈的十年安全性和療效數據支持的 –
– Ocrevus Zunovo offers people with multiple sclerosis (MS) more options to access treatment based on their individual needs –
– Ocrevus Zunovo爲多發性硬化（MS）患者提供更多根據個體需求進行治療的選擇 –
Genentech, a member of the Roche Group ((SIX: RO, ROG, OTCQX:RHHBY), announced today that the United States Food and Drug Administration (U.S. FDA) has approved Ocrevus Zunovo (ocrelizumab & hyaluronidase-ocsq) for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS). Ocrevus Zunovo is the first and only twice-a-year, healthcare professional (HCP)-administered approximately 10-minute subcutaneous (SC) injection approved for both these forms of multiple sclerosis, giving people living with MS more treatment options.
羅氏集團成員亨利製藥公司今日宣佈，美國食品和藥物管理局（FDA）已批准Ocrevus Zunovo（奧克雷利珠單抗和透明質酸酶-ocsq）用於治療複發性多發性硬化症（RMS）和原發性進行性多發性硬化症（PPMS）。Ocrevus Zunovo是首款也是唯一一款每年兩次由專業醫療人員（HCP）進行約10分鐘皮下（SC）注射的批准藥物，可用於這兩種形式的多發性硬化症治療，爲患有多發性硬化症的人提供更多治療期權。
譯文內容由第三人軟體翻譯。